Safe and effective treatment of follicular lymphoma in patients with HCV-infection

Hematol Oncol. 2020 Oct;38(4):604-606. doi: 10.1002/hon.2751. Epub 2020 Jun 23.

Authors

Ekaterina Nesterova¹, Elena Tanaschuk², Dzhamal Abdurakhmanov², Eduard Gemdzhian¹, Sergey Kravchenko¹, Yana Mangasarova¹, Inna Krasilnikova¹, Madina Bagova¹

Affiliations

¹ National Research Center for Hematology, Moscow, Russian Federation.
² Sechenov University, Moscow, Russian Federation.

PMID: 32483905
DOI: 10.1002/hon.2751

No abstract available

Keywords: HCV; direct-acting antivirals; follicular lymphoma; immunochemotherapy; overall survival.

Publication types

Letter
Observational Study

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antiviral Agents / administration & dosage*
Antiviral Agents / adverse effects
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Cytomegalovirus / metabolism*
Cytomegalovirus Infections* / blood
Cytomegalovirus Infections* / drug therapy
Cytomegalovirus Infections* / mortality
Disease-Free Survival
Doxorubicin / administration & dosage
Doxorubicin / adverse effects
Female
Humans
Lymphoma, Follicular* / blood
Lymphoma, Follicular* / drug therapy
Lymphoma, Follicular* / mortality
Male
Middle Aged
Prednisone / administration & dosage
Prednisone / adverse effects
RNA, Viral / blood*
Rituximab / administration & dosage
Rituximab / adverse effects
Survival Rate
Vincristine / administration & dosage
Vincristine / adverse effects

Substances

Antiviral Agents
R-CHOP protocol
RNA, Viral
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone